Stoke down as FDA rebuffs expedited review of zorevunersen for Dravet syndrome
Source: SeekingAlpha
2026-01-12 10:11:57 ET
More on Stoke Therapeutics
- Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating
- Seeking Alpha’s Quant Rating on Stoke Therapeutics
- Historical earnings data for Stoke Therapeutics
- Financial information for Stoke Therapeutics
Read the full article on Seeking Alpha
For further details see:
Stoke down as FDA rebuffs expedited review of zorevunersen for Dravet syndrome
Stoke Therapeutics Inc.
NASDAQ: STOK
STOK Trading
4.61% G/L:
$39.50 Last:
657,076 Volume:
$39.06 Open:
STOK Latest News
March 04, 2026 05:06:00 pm
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
February 24, 2026 04:01:00 pm
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 11, 2026 07:30:00 am
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
February 04, 2026 04:01:00 pm
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
STOK Stock Data
$1,859,163,232
44,494,260
1.78%
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Bedford
